Sophia Genetics (SOPH) Stock
Technology sector company. Here's the price, business snapshot, and what's worth knowing about Sophia Genetics in October 2026.
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics (SOPH) Stock Forecast
Analyst price target, next 12 months
$8.80
+8.8% vs today's $8.09
Price range over the last 12 months
Close to its 12-month high
Analysts covering Sophia Genetics have a consensus 12-month target of $8.80, above the current price of $8.09.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 6 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts are very positive about SOPHIA GENETICS stock, suggesting it could reach $8.8 soon.
Financial Health
SOPHIA GENETICS is doing well with strong revenues and cash flow, showing solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
